Results 231 to 240 of about 547,234 (309)

Altered Nasal Microbiota in Sinonasal Tumors: A Comparative Analysis of Malignant and Benign Sinonasal Tumors

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Although shifts in nasal microbiota have been well‐documented in inflammatory upper airway conditions, microbiota tumor‐associated alterations remain uncharacterized. This study is the first to compare sinonasal microbiota profiles of patients with malignant tumors (MT), benign tumors (BT), and controls, offering insights into tumor‐
Evan A. Patel, Phillip A. Engen, Glen D. Souza, Sarah Khalife, Donyea Moore, Lauren Kret, Pedro Escobedo, Stefan J. Green, Ankur Naqib, Peter Filip, Peter Papagiannopoulos, Bobby A. Tajudeen, Mahboobeh Mahdavinia, Pete S. Batra   +13 more
wiley   +1 more source

Radiation Oncology Follow-Up of Prostate Cancer Survivors Following Completion of Radiotherapy: A Population-Based Study. [PDF]

Curr Oncol
Cerasuolo JO, Sussman J, Dayes IS, Sutradhar R, Zargoush M, Seow H.   +5 more
europepmc   +1 more source

Collateral Damage: How Medicaid Cuts Under the One Big Beautiful Bill Act Threaten Rural Radiation Oncology. [PDF]

Cureus
Panse D, Wassel M, Yu C, Rowley JP, Sindhu KK.   +4 more
europepmc   +1 more source

Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies

Animal Models and Experimental Medicine, EarlyView.
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang, Baoying Xu, Xinru Chen, Yu Chen, Dehong Yu   +4 more
wiley   +1 more source

AI in Radiation Oncology: A Comprehensive Review of Current Applications and Future Directions. [PDF]

Cureus
Zafar F, Vilsan J, Mani S, Al Yousif AR, Cano-Reyes SE, Abraham G, de Barros Neto JF, Imam B, Aluko M, Sikdar S.   +9 more
europepmc   +1 more source

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities [PDF]

, 2018
et al,, Michalski, Jeff M
core   +1 more source

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

Leveraging large language models to populate structured clinical case report forms from unstructured medical notes in radiation oncology. [PDF]

Clin Transl Radiat Oncol
Nachbar M, Yi N, Büttner M, Gani C, Niyazi M, Garcia-Agundez A, Eickhoff C, Thorwarth D.   +7 more
europepmc   +1 more source

Selenium Nanomaterials for Wound Healing: Synergistic Strategies from Anti‐Infection to Tissue Regeneration

Advanced NanoBiomed Research, EarlyView.
Selenium nanoparticles (SeNPs) are emerging as multifunctional platforms for wound healing, integrating antimicrobial, anti‐inflammatory, and proregenerative activities. This review summarises key mechanisms and recent advances in SeNP‐enabled composite dressings, immunomodulatory nanocomposites, microenvironment‐responsive hydrogels, photothermal and ...
Yangxia Chen, Xiaoshuang Liang, Sirui Li, Shuoshan Li, Wei Liu, Yingping Lin, Siqi Li, Zehang Zhang, Judun Zheng, Tianfeng Chen, Rongyi Chen   +10 more
wiley   +1 more source

Heterogenous Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential

Advanced NanoBiomed Research, EarlyView.
Glioblastoma mortality is driven by cell invasion and therapeutic resistance. We report a cancer engineering approach to evaluate the behavior of heterogeneous cohorts of temozolomide resistant and responsive GBM cells. We show the effect of physiologically‐relevant metronomic dosing on ensemble drug response and invasion.
Victoria A. Kriuchkovskaia, Ela K. Eames, Sydney A. McKee, Paul J. Hergenrother, Rebecca B. Riggins, Brendan A. C. Harley   +5 more
wiley   +1 more source